• Immunotech Laboratories’ IPF Shows Significant Antiviral Activity in Lab Study

    Posted Fri, 05/08/2009

    (Vilnius, Lithuania and Glendale, Calif. -- 28 April 2009) A research team from Immunotech Laboratories (NASDQ: IMMB.PK) presented data indicating that the Company’s Irreversible Pepsin Fraction (IPF) displays significant antiviral activity without indications of resistance. The lab data were presented by Harry Zhabilov, Chief Science Officer, Immunotech Laboratories at the 5th European Conference on Clinical and Social Research on AIDS and Drugs, Vilnius, Lithuania.

  • Immunotech Laboratories Announces South American Strategy

    Posted Fri, 04/03/2009

    Immunotech Laboratories (IMMB) is happy to announce preliminary discussions in setting up a potential venture for South America, headquartered in Mexico.

    According to Ara Ghanime, Chairman of Immunotech Laboratories, the potential outcome from these discussions will enhance the company's efforts for its preclinical activities and position the company for a viable regional market penetration. Additional information will be provided as the company continues to implement its South American strategy. Immunotech's management is committed to bringing its corporate mission to fruition utilizing its novel therapeutic platform of Irreversible Pepsin Fraction (IPF) for the treatment of HIV/AIDS.

  • Beating HIV/AIDS - Immunotech Participation in DART Conference

    Posted Wed, 04/01/2009

    Immunotech Laboratories announces successful Participation in DART conference in Puerto Rico with its abstract "Irreversible Pepsin Fraction (IPF) displays significant antiretroviral activity via specific novel cytokine stimulation in vitro investigation of activity on human lymphocytes."

    Additionally, Immunotech will present at the 5th European Conference on Clinical and Social Research on AIDS and Drugs, with its abstract titled "IPF displays significant Antiviral activity in vitro without provoking the presentation of resistant profiles of minority subspecies."

  • Immunotech Completes Merger Acquisition

    Posted Mon, 03/30/2009

    Immunotech Laboratories, Inc. has completed a reverse merger with a public shell company and has restructured its position through a 100 to 1 reverse split of stock. The company has issued 60 million shares from authorized bringing the total number of issued and outstanding shares to 60,555,688 shares trading under NASDAQ OTC.PK Exchange ticker symbol IMMB.

    Immunotech Laboratories Inc. has indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. IPF has demonstrated to have both fusion inhibitor and immunomodulator capabilities during in vitro studies with no viral resistance. This provides opportunities for patients that have already shown resistance to one or more antiretroviral therapies.

© 2009 - Immunotech Laboratories, Inc.

Site Design by 4HDM